Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160

The effects of treatment with a bombesin receptor antagonist [D‐Tpi6, Leu13Ψ(CH2NH) Leu14]BN(6–14)(RC‐3095) and the combination of an agonist of luteinizing hormone‐releasing hormone [D‐Trp6]‐LH‐RH and somatostatin analog D‐Phe‐Cys‐Tyr‐D‐Trp‐Lys‐Val‐Cys‐Trp‐NH2 (RC‐160) were studied in nude mice bearing xenografts of the hormone‐dependent human prostate tumor PC‐82. During the 5 weeks of treatment, tumor growth was decreased in all treated groups compared with controls. Bombesin antagonist RC‐3095 and the combination of [D‐Trp6]‐LH‐RH and RC‐160 caused a greater inhibition of tumor growth than [D‐Trp6]‐LH‐RH or RC‐160 alone as based on measurement of tumor volume and percentage change in tumor volume. The largest decrease in tumor weight was also seen in the groups treated with the bombesin antagonist and with the combination of RC‐160 and [D‐Trp6]‐LH‐RH. Serum prostatic‐specific antigen levels were greatly decreased, and insulin‐like growth factor I (IGF‐I) as well as growth hormone levels were reduced in all treated groups. Specific binding sites for [D‐Trp6]‐LH‐RH, epidermal growth factor (EGF), IGF‐I, and somatostatin (SS‐14) were found in the tumor membranes. Receptors for EGF were significantly down‐regulated by treatment with the bombesin antagonist or RC‐160. Combination of LH‐RH agonists with somatostatin analog RC‐160 might be considered for improvement of hormonal therapy for prostate cancer. The finding that bombesin antagonist RC‐3095 inhibits the growth of PC‐82 prostate cancer suggests the merit of further studies to evaluate the possible usefulness of antagonists of bombesin in the management of prostatic carcinoma.